ArticleFrontiers in public health2026
Validation of digital PCR as a complementary tool to MS2 plaque assay for virucidal activity assessment.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bacteriophage MS2 is widely applied as a surrogate for pathogenic non-enveloped RNA viruses that are difficult to culture. However, standardized approaches for evaluating disinfectant efficacy using MS2 remain limited. This study aimed to validate dPCR as a rapid quantitative complement to the previously established MS2 plaque assay, assessing their concordance in disinfectant efficacy testing using a previously established double-layer protocol. Methods: A previously established double-layer MS2 plaque assay was employed. Disinfectant efficacy was tested against two widely used agents-70% ethanol and 60 ppm hypochlorous acid (HOCl)-according to the Korean Disinfectant Efficacy Test Guideline. Viral reduction was determined by plaque counts and further quantified by dPCR following RNase treatment to eliminate free RNA. Agreement between the established plaque assay and dPCR was evaluated using regression and Bland-Altman analyses. Results: Treatment with 70% ethanol yielded only partial inactivation, with a 2.43-log10 reduction, below the ≥4-log10 benchmark for virucidal efficacy. In contrast, 60 ppm HOCl achieved a 4.38-log10 reduction, confirming effective MS2 inactivation. The dPCR counts correlated strongly with plaque counts (R = 0.999), and Bland-Altman analysis demonstrated excellent agreement within 95% confidence limits, supporting dPCR as a practical alternative to plaque assays. However, the reliability of dPCR as a proxy at low viral concentrations near the limit of detection (<10 Conclusion: This study successfully validated dPCR as a rapid quantitative complement to the previously established MS2 double-layer plaque assay, demonstrating its utility in disinfectant efficacy testing. The findings confirm ethanol's limited virucidal capacity against MS2 and HOCl's effectiveness at low concentrations. These results establish dPCR as a promising molecular tool that complements plaque assay results for comprehensive viral surrogate evaluation in disinfection studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.